Russian Biotech Firm Targets 2027 for First Human-Compatible Pig Kidney

NOVOSIBIRSK, March 11 – A Russian biotechnology company is aiming to produce the country's first genetically modified mini-pig by early 2027, with the goal of using its kidney as a temporary transplant for humans. Eduard Chuiko, CEO of M-Genomics, a resident firm of the Novosibirsk Academpark, outlined the ambitious timeline in an interview.

Chuiko stated that, with proper infrastructure and funding, the initial animal could be ready in under a year, but a more realistic target is the first half of 2027. The broader objective is to establish a viable pipeline for xenotransplantation—the transfer of animal organs to humans—by 2030. The kidney is the primary focus for this initial effort.

He was careful to temper expectations, noting the first-generation organ would be a bridge, not a permanent solution. 'This initial organ won't allow someone to live for months or years,' Chuiko explained. 'It would be designed to function without rejection for days. As we refine the technology, it could save many lives by sustaining patients while they wait for a human donor.'

The project team, which includes scientists from the Institute of Cytology and Genetics and the Meshalkin National Medical Research Center, has overcome the core scientific hurdles. The primary challenges now are financial and logistical. 'This is an expensive, long-term project,' Chuiko said. 'We are seeking partners who are interested in collaborating on this work.'

Source: RIA Novosti